About Mersana Therapeutics, Inc.
https://www.mersana.comMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
CEO
Martin H. Huber
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-28 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
NEXTECH INVEST LTD.
Shares:12.07M
Value:$350.92M
BLACKROCK INC.
Shares:8.38M
Value:$243.8M
BOXER CAPITAL, LLC
Shares:1.82M
Value:$52.84M
Summary
Showing Top 3 of 38
About Mersana Therapeutics, Inc.
https://www.mersana.comMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.01M ▲ | $18.48M ▼ | $-7.54M ▲ | -68.53% ▲ | $-1.51 ▲ | $-7.07M ▲ |
| Q2-2025 | $3.06M ▲ | $23.35M ▼ | $-24.3M ▼ | -795.03% ▲ | $-4.87 ▼ | $-23.34M ▼ |
| Q1-2025 | $2.75M ▼ | $27.27M ▼ | $-24.12M ▼ | -875.93% ▼ | $-4.85 ▼ | $-23.03M ▼ |
| Q4-2024 | $16.36M ▲ | $31.17M ▲ | $-14.12M ▼ | -86.28% ▲ | $-2.86 ▼ | $-12.81M ▼ |
| Q3-2024 | $12.6M | $24.67M | $-11.5M | -91.29% | $-2.34 | $-9.7M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $56.39M ▼ | $62.69M ▼ | $122.22M ▼ | $-59.54M ▼ |
| Q2-2025 | $76.97M ▼ | $84.57M ▼ | $137.72M ▼ | $-53.15M ▼ |
| Q1-2025 | $102.29M ▼ | $112.47M ▼ | $143.34M ▼ | $-30.87M ▼ |
| Q4-2024 | $134.62M ▼ | $144.66M ▼ | $154.17M ▼ | $-9.51M ▼ |
| Q3-2024 | $155.17M | $169.53M | $168.48M | $1.05M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.54M ▲ | $-3.19M ▲ | $372K ▼ | $-17.76M ▼ | $-20.58M ▲ | $-3.19M ▲ |
| Q2-2025 | $-24.3M ▼ | $-22.6M ▲ | $395K ▼ | $-3.11M ▲ | $-25.32M ▼ | $-22.6M ▲ |
| Q1-2025 | $-24.12M ▼ | $-29.33M ▼ | $27M ▼ | $-3.14M ▼ | $-5.46M ▼ | $-29.33M ▼ |
| Q4-2024 | $-14.12M ▼ | $-19.25M ▼ | $50M ▲ | $-1.87M ▼ | $28.88M ▲ | $-19.25M ▼ |
| Q3-2024 | $-11.5M | $-8.58M | $28.47M | $-23K | $19.87M | $-8.58M |
CEO
Martin H. Huber
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-28 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
NEXTECH INVEST LTD.
Shares:12.07M
Value:$350.92M
BLACKROCK INC.
Shares:8.38M
Value:$243.8M
BOXER CAPITAL, LLC
Shares:1.82M
Value:$52.84M
Summary
Showing Top 3 of 38